Celyad SA (CYAD) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Celyad SA (CYAD) has a cash flow conversion efficiency ratio of 0.177x as of December 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-2.85 Million ≈ $-3.33 Million USD) by net assets (€-16.12 Million ≈ $-18.85 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see CYAD stock market capitalisation for the company's overall valuation and market capitalisation.
Celyad SA - Cash Flow Conversion Efficiency Trend (2010–2024)
This chart illustrates how Celyad SA's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Celyad SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Celyad SA ranked by their cash flow conversion efficiency. See how well can Celyad SA service its debt to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ignite Ltd
AU:IGN
|
0.302x |
|
Soc Franc Casinos
PA:SFCA
|
0.092x |
|
Locate Technologies Ltd
AU:LOC
|
-0.104x |
|
Crown Point Energy Inc
V:CWV
|
-0.370x |
|
BAIYU Holdings Inc.
NASDAQ:BYU
|
-0.009x |
|
Rma Global Ltd
AU:RMY
|
0.273x |
|
WAG Payment Solutions PLC
LSE:WPS
|
0.305x |
|
Wolfden Resources Corporation
V:WLF
|
-0.231x |
Annual Cash Flow Conversion Efficiency for Celyad SA (2010–2024)
The table below shows the annual cash flow conversion efficiency of Celyad SA from 2010 to 2024. View latest Celyad SA stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €-16.12 Million ≈ $-18.85 Million |
€-5.68 Million ≈ $-6.64 Million |
0.352x | +114.61% |
| 2023-12-31 | €6.30 Million ≈ $7.37 Million |
€-15.20 Million ≈ $-17.77 Million |
-2.411x | +62.83% |
| 2022-12-31 | €4.32 Million ≈ $5.05 Million |
€-28.01 Million ≈ $-32.75 Million |
-6.488x | -962.73% |
| 2021-12-31 | €43.64 Million ≈ $51.02 Million |
€-26.64 Million ≈ $-31.15 Million |
-0.611x | +31.60% |
| 2020-12-31 | €30.99 Million ≈ $36.24 Million |
€-27.66 Million ≈ $-32.34 Million |
-0.893x | -44.38% |
| 2019-12-31 | €45.62 Million ≈ $53.33 Million |
€-28.20 Million ≈ $-32.97 Million |
-0.618x | -26.12% |
| 2018-12-31 | €55.59 Million ≈ $64.99 Million |
€-27.25 Million ≈ $-31.86 Million |
-0.490x | +52.97% |
| 2017-12-31 | €47.53 Million ≈ $55.57 Million |
€-49.55 Million ≈ $-57.93 Million |
-1.042x | -283.66% |
| 2016-12-31 | €90.88 Million ≈ $106.25 Million |
€-24.69 Million ≈ $-28.87 Million |
-0.272x | -10.92% |
| 2015-12-31 | €111.47 Million ≈ $130.32 Million |
€-27.30 Million ≈ $-31.92 Million |
-0.245x | +62.47% |
| 2014-12-31 | €26.68 Million ≈ $31.20 Million |
€-17.41 Million ≈ $-20.36 Million |
-0.653x | -3.66% |
| 2013-12-31 | €16.90 Million ≈ $19.76 Million |
€-10.64 Million ≈ $-12.44 Million |
-0.630x | -109.91% |
| 2012-12-31 | €-1.31 Million ≈ $-1.53 Million |
€-8.34 Million ≈ $-9.75 Million |
6.352x | +169.92% |
| 2011-12-31 | €840.11K ≈ $982.18K |
€-7.63 Million ≈ $-8.92 Million |
-9.084x | -848.39% |
| 2010-12-31 | €8.69 Million ≈ $10.16 Million |
€-8.32 Million ≈ $-9.73 Million |
-0.958x | -- |
About Celyad SA
Celyad Oncology SA, a biotechnology company, focuses on the research and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through Immuno-Oncology and Cardiology segments. The company develops short hairpin ribonucleic acid (shRNA) non-gene-edited technology, which allows for the development of allogenic CAR T-cells through the modulation of genes encoding … Read more